keyword
MENU ▼
Read by QxMD icon Read
search

statin in acute coronary syndrome

keyword
https://www.readbyqxmd.com/read/29288404/paradoxical-impact-of-decreased-low-density-lipoprotein-cholesterol-level-at-baseline-on-the-long-term-prognosis-in-patients-with-acute-coronary-syndrome
#1
Takuya Nakahashi, Hayato Tada, Kenji Sakata, Yohei Yakuta, Yoshihiro Tanaka, Akihiro Nomura, Tadatsugu Gamou, Hidenobu Terai, Yuki Horita, Masatoshi Ikeda, Masanobu Namura, Masayuki Takamura, Kenshi Hayashi, Masakazu Yamagishi, Masa-Aki Kawashiri
Although statin therapy is beneficial in the setting of acute coronary syndrome (ACS), a substantial proportion of patients with ACS still do not receive the guideline-recommended lipid management in contemporary practice. We hypothesize that the low-density lipoprotein cholesterol (LDL-C) level at the time of admission might affect patient management and the subsequent outcome. Nine-hundred and forty-two consecutive patients with ACS who underwent percutaneous coronary intervention were analyzed retrospectively...
December 29, 2017: Heart and Vessels
https://www.readbyqxmd.com/read/29279527/impact-of-water-and-lipid-soluble-statins-on-nonculprit-lesions-in-patients-with-acute-coronary-syndrome
#2
Yu Ishikawa, Tomonori Itoh, Mamoru Satoh, Tetsuya Fusazaki, Shoma Sugawara, Satoshi Nakajima, Motoyuki Nakamura, Yoshihiro Morino
Statins can be differentiated into two types, based on their solubility, which have potentially differing effects on the coronary artery wall. However, suspected differences in statins' effects on plaque composition have not been systemically investigated.Sixty-seven patients with acute coronary syndrome (ACS) were randomly assigned to either atorvastatin (10 mg/day) or rosuvastatin (2.5 mg/day). Intravascular ultrasound (IVUS) and integrated backscatter (IB)-IVUS, an established tool to quantify each plaque's components, were performed immediately after emergent percutaneous coronary intervention (PCI)...
December 27, 2017: International Heart Journal
https://www.readbyqxmd.com/read/29274187/sex-differences-in-diagnoses-treatment-and-outcomes-for-emergency-department-patients-with-chest-pain-and-elevated-cardiac-troponin
#3
Karin H Humphries, May K Lee, Mona Izadnegahdar, Min Gao, Daniel T Holmes, Frank X Scheuermeyer, Martha Mackay, Andre Mattman, Eric Grafstein
OBJECTIVE: While sex differences in the treatment and outcomes of subjects with acute coronary syndromes are well documented, little is known about the impact of cardiac troponin (cTn) levels obtained in the emergency department (ED) on the observed sex differences. We sought to determine whether cTn levels by chest pain features modify sex differences in diagnosis, treatment and outcomes in patients presenting with chest pain suggestive of ischemia. METHODS: All adults presenting to two hospitals in Vancouver, Canada between May 2008 and Mar 2013 with ischemic chest pain and with cTn testing were included in the study...
December 23, 2017: Academic Emergency Medicine: Official Journal of the Society for Academic Emergency Medicine
https://www.readbyqxmd.com/read/29258913/evaluation-of-dyslipidaemia-and-the-impact-of-hypolipidemic-therapy-on-prognosis-in-high-and-very-high-risk-patients-through-the-hyperlipidaemia-therapy-in-tertiary-cardiological-center-tercet-registry
#4
Krzysztof Dyrbuś, Tadeusz Osadnik, Piotr Desperak, Aneta Desperak, Mariusz Gąsior, Maciej Banach
The use of statins in the treatment of hyperlipidaemia leads to a significant decrease in cardiovascular (CV) endpoints, and therapy effects are proportional to the reduction of cholesterol levels. In Poland, information about the effects of statin therapy is scarcely available. The information gathered in the Hyperlipidaemia Therapy in the tERtiary Cardiological cEnTer (TERCET) Registry on high-risk and very high-risk patients might improve our knowledge on this issue and help to introduce suitable activities...
December 16, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29234694/contemporary-data-on-treatment-practices-for-low-density-lipoprotein-cholesterol-in-3867-patients-who-had-suffered-an-acute-coronary-syndrome-across-the-world
#5
Anselm K Gitt, Dominik Lautsch, Jean Ferrières, Gaetano M De Ferrari, Ami Vyas, Carl A Baxter, Lori D Bash, Veronica Ashton, Martin Horack, Wael Almahmeed, Fu-Tien Chiang, Kian Keong Poh, Philippe Brudi, Baishali Ambegaonkar
DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7% received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4...
February 2018: Data in Brief
https://www.readbyqxmd.com/read/29212965/effects-of-ezetimibe-statin-combination-therapy-on-coronary-atherosclerosis-in-acute-coronary-syndrome
#6
Kiyoshi Hibi, Shinjo Sonoda, Masanori Kawasaki, Yutaka Otsuji, Toyoaki Murohara, Hideki Ishii, Katsuhiko Sato, Ryoji Koshida, Yukio Ozaki, Masataka Sata, Yoshihiro Morino, Tadashi Miyamoto, Tetsuya Amano, Satoshi Morita, Ken Kozuma, Kazuo Kimura, Hisayoshi Fujiwara
BACKGROUND: The results of previous clinical trials on the effects of ezetimibe-statin combination therapy on atherosclerosis are inconsistent, and the anti-atherosclerotic effect of ezetimibe remains controversial.Methods and Results:We conducted a prospective, randomized open-label study at 10 centers. One hundred and twenty-eight statin-naïve patients with acute coronary syndrome (ACS) undergoing intravascular ultrasound (IVUS)-guided percutaneous coronary intervention were randomized to receive either 2 mg/day pitavastatin plus 10 mg/day ezetimibe, or 2 mg/day pitavastatin...
December 7, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29197254/utilization-of-lipid-modifying-therapy-and-low-density-lipoprotein-cholesterol-goal-attainment-in-patients-at-high-and-very-high-cardiovascular-risk-real-world-evidence-from-germany
#7
Winfried März, Franz-Werner Dippel, Karlheinz Theobald, Katherine Gorcyca, Şerban R Iorga, David Ansell
BACKGROUND AND AIMS: Elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for cardiovascular (CV) events. European guidelines recommend reducing LDL-C as the primary lipid target to reduce CV risk, using lifestyle modifications and lipid-lowering therapy (LLT). Many European patients do not achieve guideline-recommended LDL-C levels. The present database analysis aimed to assess LLT treatment patterns and LDL-C threshold attainment in Germany in a large, real-world cohort of patients...
November 20, 2017: Atherosclerosis
https://www.readbyqxmd.com/read/29174015/effect-of-statin-therapy-on-the-prevention-of-new-onset-acute-coronary-syndrome-in-patients-with-rheumatoid-arthritis
#8
Chen-Yu Huang, Ting-Tse Lin, Yao-Hsu Yang, Lian-Yu Lin, Chia-Ti Tsai, Juey-Jen Hwang, Pau-Chung Chen, Jiunn-Lee Lin
BACKGROUND: The aim of this study is to investigate whether statin therapy can reduce new-onset acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA). METHODS: We used a database from the Registry for Catastrophic Illness from the National Health Research Institute (NHRI) in Taiwan. All RA patients aged 18 or older, diagnosed between 1995 and 2013, without previous cardiovascular events were included. We divided participants into quartiles according to the accumulated statin equivalent dosage and tertiles of period of days of statin treatment to examine the possible dose-response effect...
November 11, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29168689/in-hospital-prescriptions-of-secondary-prevention-medications-for-post-acute-coronary-syndrome-patients-in-south-korea%C3%A2
#9
Han-Bin Kang, Minwook Choi, Sang Gyeong Yoon, Young Seuk Cho, Nam Kyung Je
BACKGROUND: Optimal medical therapy and the management of cardiac risk factors are crucial for the secondary prevention of acute coronary syndrome (ACS). However, there have been reports on the underutilization of secondary-prevention medications for ACS. This study aimed to investigate adherence of in-hospital prescriptions to clinical practice guidelines for the secondary prevention of ACS using real-world data. MATERIALS AND METHODS: We collected information on ACS patients from national insurance claims data...
January 2018: International Journal of Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29167415/ticagrelor-leads-to-statin-induced-rhabdomyolysis-a-case-report
#10
Simone M Mrotzek, Tienush Rassaf, Matthias Totzeck
BACKGROUND Following acute coronary intervention in cardiology patients, the combined medical therapy with the platelet inhibitory drug ticagrelor and a statin medication (e.g., simvastatin) is recommended according to international guidelines. Yet combined therapeutic regimens have the potential of pharmacological interaction with both ticagrelor and simvastatin being metabolized by CYP3A4. Rhabdomyolysis is a known side-effect of statin therapy and combined therapy increases the susceptibility to this complication...
November 23, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29151034/efficacy-and-safety-of-adding-ezetimibe-to-statin-therapy-among-women-and-men-insight-from-improve-it-improved-reduction-of-outcomes-vytorin-efficacy-international-trial
#11
Eri Toda Kato, Christopher P Cannon, Michael A Blazing, Erin Bohula, Sema Guneri, Jennifer A White, Sabina A Murphy, Jeong-Gun Park, Eugene Braunwald, Robert P Giugliano
BACKGROUND: IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) showed that adding the nonstatin ezetimibe to statin therapy further reduced cardiovascular events in patients after an acute coronary syndrome. In a prespecified analysis, we explore results stratified by sex. METHODS AND RESULTS: In IMPROVE-IT, patients with acute coronary syndrome and low-density lipoprotein cholesterol of 50 to 125 mg/dL were randomized to placebo/simvastatin 40 mg or ezetimibe/simvastatin 10/40 mg...
November 18, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29122809/eligibility-for-pcsk9-inhibitors-according-to-american-college-of-cardiology-acc-and-european-society-of-cardiology-european-atherosclerosis-society-esc-eas-guidelines-after-acute-coronary-syndromes
#12
Baris Gencer, Konstantinos C Koskinas, Lorenz Räber, Alexios Karagiannis, David Nanchen, Reto Auer, David Carballo, Sebastian Carballo, Roland Klingenberg, Dik Heg, Christian M Matter, Thomas F Lüscher, Nicolas Rodondi, François Mach, Stephan Windecker
BACKGROUND: The American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) have recently published recommendations for the use of proprotein convertase subtilisin/kexin-9 (PCSK9) inhibitors in situations of very high risk. We aim to assess in the real world the suitability of PCSK9 inhibitors for acute coronary syndromes. METHODS AND RESULTS: We analyzed a prospective Swiss cohort of 2023 patients hospitalized for acute coronary syndromes between 2009 and 2014 with available data for low-density lipoprotein cholesterol and lipid-lowering therapy at 1 year...
November 9, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29092845/clinical-predictors-for-lack-of-favorable-vascular-response-to-statin-therapy-in-patients-with-coronary-artery-disease-a-serial-optical-coherence-tomography-study
#13
Yoshiyasu Minami, Zhao Wang, Aaron D Aguirre, Daniel S Ong, Chong-Jin Kim, Shiro Uemura, Tsunenari Soeda, Hang Lee, James Fujimoto, Ik-Kyung Jang
BACKGROUND: Previous studies have demonstrated that statin therapy improves cardiac outcomes, probably by stabilizing thin-cap fibroatheroma in patients with coronary artery disease. However, major adverse cardiac events still occur in some patients, despite statin therapy. The aim of this study is to identify clinical predictors for the lack of a favorable vascular response to statin therapy in patients with coronary artery disease. METHODS AND RESULTS: A total of 140 nonculprit plaques from 84 patients with coronary artery disease who were treated with a statin and had serial optical coherence tomography imaging (median interval, 6...
November 1, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/29071331/association-of-lipoprotein-a-with-risk-of-recurrent-ischemic-events-following-acute-coronary-syndrome-analysis-of-the-dal-outcomes-randomized-clinical-trial
#14
Gregory G Schwartz, Christie M Ballantyne, Philip J Barter, David Kallend, Lawrence A Leiter, Eran Leitersdorf, John J V McMurray, Stephen J Nicholls, Anders G Olsson, Prediman K Shah, Jean-Claude Tardif, John Kittelson
Importance: It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS). Objective: To determine the association of Lp(a) concentration measured after ACS with the subsequent risk of ischemic cardiovascular events. Design, Setting, and Participants: This nested case-cohort analysis was performed as an ad hoc analysis of the dal-Outcomes randomized clinical trial...
October 25, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/29056945/comparison-of-the-low-density-lipoprotein-cholesterol-target-value-and-the-preventive-effect-of-statins-in-elderly-patients-and-younger-patients
#15
Akihiro Endo, Taiji Okada, Misun Pak, Yuzo Kagawa, Shimpei Ito, Hirotomo Sato, Kenji Kageshima, Yasuyuki Yoshida, Kazuaki Tanabe
OBJECTIVE: To assess whether the low-density lipoprotein cholesterol (LDL-C) target value and preventive effect of statins are different between elderly and younger patients. METHODS: We investigated 304 patients with previous percutaneous coronary intervention who underwent coronary angiography from January 2007 to December 2016 for examination of recurrent ischemia beyond the early restenosis. Patients were classified into two groups: age ≥ 75 years (elderly group: n = 140) and < 75 years (younger group: n = 164)...
June 2017: Journal of Geriatric Cardiology: JGC
https://www.readbyqxmd.com/read/29055633/colchicine-therapy-and-plaque-stabilization-in-patients-with-acute%C3%A2-coronary-syndrome-a-ct-coronary-angiography-study
#16
Kaivan Vaidya, Clare Arnott, Gonzalo J Martínez, Bernard Ng, Samuel McCormack, David R Sullivan, David S Celermajer, Sanjay Patel
OBJECTIVES: The authors sought to evaluate the plaque-modifying effects of low-dose colchicine therapy plus optimal medical therapy (OMT) in patients post-acute coronary syndrome (ACS), as assessed by coronary computed tomography angiography (coronary CTA). BACKGROUND: Colchicine therapy has been postulated to have beneficial anti-inflammatory effects in patients with ACS, translating into reduction in future adverse cardiovascular events. However, whether favorable plaque modification underpins this is yet unproven...
October 14, 2017: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29049325/effect-of-therapeutic-interchange-on-medication-reconciliation-during-hospitalization-and-upon-discharge-in-a-geriatric-population
#17
Jessica S Wang, Robert L Fogerty, Leora I Horwitz
BACKGROUND: Therapeutic interchange of a same class medication for an outpatient medication is a widespread practice during hospitalization in response to limited hospital formularies. However, therapeutic interchange may increase risk of medication errors. The objective was to characterize the prevalence and safety of therapeutic interchange. METHODS AND FINDINGS: Secondary analysis of a transitions of care study. We included patients over age 64 admitted to a tertiary care hospital between 2009-2010 with heart failure, pneumonia, or acute coronary syndrome who were taking a medication in any of six commonly-interchanged classes on admission: proton pump inhibitors (PPIs), histamine H2-receptor antagonists (H2 blockers), hydroxymethylglutaryl CoA reductase inhibitors (statins), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and inhaled corticosteroids (ICS)...
2017: PloS One
https://www.readbyqxmd.com/read/29040268/benefit-and-harm-of-intensive-blood-pressure-treatment-derivation-and-validation-of-risk-models-using-data-from-the-sprint-and-accord-trials
#18
Sanjay Basu, Jeremy B Sussman, Joseph Rigdon, Lauren Steimle, Brian T Denton, Rodney A Hayward
BACKGROUND: Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. We sought to develop and validate risk models for predicting absolute risk difference (increased risk or decreased risk) for CVD events and serious adverse events from intensive BP therapy. A secondary aim was to test if the statistical method of elastic net regularization would improve the estimation of risk models for predicting absolute risk difference, as compared to a traditional backwards variable selection approach...
October 2017: PLoS Medicine
https://www.readbyqxmd.com/read/29033508/predictors-of-mortality-in-elderly-patients-with-non-st-elevation-acute-coronary-syndrome-data-from-taiwan-acute-coronary-syndrome-full-spectrum-registry
#19
Cheng-Chun Wei, Shih-Huang Lee
BACKGROUND: Some difficulties and variations remain associated with the care of elderly patients with non-ST elevation acute coronary syndrome (NSTE-ACS). METHODS: We included 1470 patients from a Taiwan nationwide registry who fulfilled the criteria of NSTE-ACS, and stratified these patients by age and evaluated the treatment, complications and outcomes in different age groups. Furthermore, we analyzed risk factors and standards of care to determine the predictors of mortality...
July 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/29028484/cholesterol-target-value-attainment-and-lipid-lowering-therapy-in-patients-with-stable-or-acute-coronary-heart-disease-results-from-the-dyslipidemia-international-study-ii
#20
Anselm K Gitt, Dominik Lautsch, Jean Ferrières, Gaetano M De Ferrari, Ami Vyas, Carl A Baxter, Lori D Bash, Veronica Ashton, Martin Horack, Wael Almahmeed, Fu-Tien Chiang, Kian Keong Poh, Philippe Brudi, Baishali Ambegaonkar
BACKGROUND AND AIMS: Low-density lipoprotein cholesterol (LDL-C) is a major contributor to cardiovascular disease. In the Dyslipidemia International Study II (DYSIS II), we determined LDL-C target value attainment, use of lipid-lowering therapy (LLT), and cardiovascular outcomes in patients with stable coronary heart disease (CHD) and those suffering from an acute coronary syndrome (ACS). METHODS: DYSIS II included patients from 18 countries. Patients with either stable CHD or an ACS were enrolled if they were ≥18 years old and had a full lipid profile available...
November 2017: Atherosclerosis
keyword
keyword
45397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"